Squamous cell carcinoma of head and neck
RecruitingA Study of Amivantamab With Carboplatin and Pembrolizumab for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
A Study of Amivantamab With Carboplatin and Pembrolizumab for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Disease:Squamous cell carcinoma of head and neck
- Substances:AmivantamabCarboplatin+3
Poland- Participants:18–64 years · 65+ years
- Substances:Amivantamab
- Sponsor:Janssen Cilag International










